BioNTech’s Pumitamig Low-Dose Surprise Steals ASCO Spotlight as Regulatory Path Sharpens
Published on 05/31/2026 at 10:10 | Redaktion boerse-global.de
The most striking detail from BioNTech’s ASCO 2026 presentation wasn’t the high response rates – it was which dose delivered them. In the phase 2/3 ROSETTA Lung-02 trial, the lower of two tested doses of the bispecific antibody Pumitamig produced the stronger result: a confirmed overall response rate (cORR) of 72.7% in squamous non-small cell lung cancer (NSCLC) and 63.6% in non-squamous disease, compared with 68.4% and 57.1% respectively at the higher dose. Across all 40 evaluable patients, the disease control rate hit 100%.
That consistency held across PD-L1 expression levels. Patients with a TPS of 50% or higher saw a complete response, while even the PD-L1-negative subgroup managed a cORR of 47.6% – a figure that underscores the breadth of the dual mechanism. Developed with Bristol Myers Squibb, Pumitamig blocks both PD-L1 and VEGF-A, combining checkpoint inhibition with anti-angiogenesis in a single molecule.
The safety profile fell within expected bounds for this therapy class. Grade 3 or higher adverse events occurred in 48.8% of patients, and only 9.3% discontinued treatment due to side effects. No fatal events were reported.
Should investors sell immediately? Or is it worth buying BioNTech?
A faster path to approval
BioNTech and BMS have recalibrated their regulatory strategy following discussions with the FDA. The phase 3 trial, now expanded to roughly 1,260 patients, uses progression-free survival (PFS) as its primary endpoint instead of overall survival. That shift allows earlier data readouts and opens the door to accelerated approval. Overall survival remains a secondary endpoint.
Market reaction and analyst support
The BioNTech share closed Friday at €82.35 on XETRA, up 2.68% on the day and roughly 3.6% for the week. On a yearly basis the stock is nearly flat and still 19% below its 52-week high of €101.90. Yet the data fuelled after-hours gains and reinforced the bullish case from UBS, which upgraded the stock to Buy on May 27 and raised its price target from $117 to $135. The analyst consensus now sits at $125.45.
BioNTech is also signalling its own conviction through a billion-dollar American depositary share buyback programme – a move management typically reserves for moments of perceived undervaluation.
The hard numbers behind the transformation
The Mainz-based company holds a liquidity reserve of €13.71 billion, funding 15 planned phase 3 studies. But the transition from COVID vaccine pure-play to oncology powerhouse comes at a steep cost: first-quarter operating losses hit €494.6 million against revenue of just €118.1 million. Pumitamig’s ASCO performance provides the first concrete evidence that this expensive pivot may deliver. The third consistent global dataset – and the surprising efficacy of the lower dose – gives investors more than just data points; it gives a clearer line of sight to a registration filing.
Ad
BioNTech Stock: New Analysis - 31 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
